![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Strong intrahepatic decline of hepatitis D virus RNA and antigen after 48 weeks of treatment with Bulevirtide in chronic HBV/HDV co-infected patients: Interim results from a multicenter, open-label, randomized phase 3 clinical trial (MYR301)
|
|
|
AASLD 2021 Nov 12-15
Lena Allweiss, Annika Volmari, Yvonne Ladiges, Corinna Eggers, Katja Giersch, Katrin Schoneweis, Vithika Suri, Jeffrey Wallin, Heiner Wedemeyer, Stephan Urban, Marc Lütgehetmann, Jan-Hendrik Bockmann, Maura Dandri
![1116211](../images/111621/111621-12/1116211.gif)
![1116212](../images/111621/111621-12/1116212.gif)
![1116213](../images/111621/111621-12/1116213.gif)
![1116214](../images/111621/111621-12/1116214.gif)
![1116215](../images/111621/111621-12/1116215.gif)
![1116216](../images/111621/111621-12/1116216.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|